- Home
- RNAZ vs ISPC Comparison
RNAZ vs ISPC Comparison
Compare RNAZ & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- ISPC
- Stock Information
- Founded
- RNAZ 2016
- ISPC 2009
- Country
- RNAZ United States
- ISPC United States
- Employees
- RNAZ N/A
- ISPC N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- RNAZ Health Care
- ISPC Health Care
- Exchange
- RNAZ Nasdaq
- ISPC Nasdaq
- Market Cap
- RNAZ 4.9M
- ISPC 4.7M
- IPO Year
- RNAZ 2021
- ISPC 2021
- Fundamental
- Price
- RNAZ $3.92
- ISPC $3.95
- Analyst Decision
- RNAZ Strong Buy
- ISPC
- Analyst Count
- RNAZ 1
- ISPC 0
- Target Price
- RNAZ $20.00
- ISPC N/A
- AVG Volume (30 Days)
- RNAZ 69.9K
- ISPC 222.6K
- Earning Date
- RNAZ 11-14-2024
- ISPC 11-07-2024
- Dividend Yield
- RNAZ N/A
- ISPC N/A
- EPS Growth
- RNAZ N/A
- ISPC N/A
- EPS
- RNAZ N/A
- ISPC N/A
- Revenue
- RNAZ N/A
- ISPC $10,390,702.00
- Revenue This Year
- RNAZ N/A
- ISPC $13.82
- Revenue Next Year
- RNAZ $233.33
- ISPC $11.76
- P/E Ratio
- RNAZ N/A
- ISPC N/A
- Revenue Growth
- RNAZ N/A
- ISPC 0.74
- 52 Week Low
- RNAZ $3.21
- ISPC $2.76
- 52 Week High
- RNAZ $264.00
- ISPC $12.20
- Technical
- Relative Strength Index (RSI)
- RNAZ 23.92
- ISPC 49.75
- Support Level
- RNAZ $6.63
- ISPC $2.76
- Resistance Level
- RNAZ $8.46
- ISPC $4.66
- Average True Range (ATR)
- RNAZ 1.05
- ISPC 0.47
- MACD
- RNAZ -0.22
- ISPC -0.02
- Stochastic Oscillator
- RNAZ 8.04
- ISPC 62.63
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.